CRISPR Therapeutics AG (CRSP), on Tuesday said it intends to offer $350 million aggregate principal amount of convertible senior notes due 2031 in a private placement.
The company said that the initial purchasers will have a 13-day option to buy up to an additional $52.5 million aggregate principal amount of the notes.
The notes will be senior unsecured obligations and will mature on March 1, 2031, unless earlier converted, redeemed, or repurchased.
Interest will be payable semiannually on March 1 and September 1 each year beginning September 1.
The company intends to use the net proceeds from the offering for general corporate purposes.
In the pre-market trading, CRSP is 8.23% lesser at $53.94 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.